Actuate Therapeutics (ACTU)
$7.46
+0.45
(+6.45%)▲
Market is closed - opens 7 PM, 07 Oct 2024
Performance
- $6.52$7.50$7.46
12.67%
Downside
Day's Volatility :13.13%
Upside
0.53%
- $5.51$10.16$7.46
26.14%
Downside
52 Weeks Volatility :45.78%
Upside
26.59%
Returns
| Period | Actuate Therapeutics | Index (Russel 2000) |
|---|---|---|
3 Months | -18.61% | 0.0% |
6 Months | -18.61% | 0.0% |
1 Year | -18.61% | 0.0% |
3 Years | -18.61% | -20.1% |
Highlights
Market Capitalization | 152.9M |
Book Value | - $63.74 |
Earnings Per Share (EPS) | -1.85 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -1.85 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Actuate Therapeutics is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Actuate Therapeutics | -14.01% | -18.61% | -18.61% | -18.61% | -18.61% |
 Regeneron Pharmaceuticals, Inc. | -10.33% | 8.11% | 21.28% | 85.63% | 257.49% |
 Novo Nordisk A/s | -12.25% | -9.71% | 24.92% | 138.38% | 343.21% |
 Alnylam Pharmaceuticals, Inc. | 9.22% | 72.73% | 52.35% | 34.04% | 250.13% |
 Vertex Pharmaceuticals Incorporated | -3.09% | 12.2% | 25.77% | 150.7% | 163.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Actuate Therapeutics | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | -63.74 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Actuate Therapeutics | NA | $152.9M | -18.61% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Company Information
Organization | Actuate Therapeutics |
Employees | 11 |
CEO | Mr. Daniel M. Schmitt |
Industry | Miscellaneous |
Discover More
Generation Income Properties Inc
$7.46
+6.45%
Touchstone Climate Transition Etf
$7.46
+6.45%
Atlas Lithium Corp
$7.46
+6.45%
Flexshares Quality Dividend
$7.46
+6.45%
Blackrock New York Muni Inc
$7.46
+6.45%
Timothy Plan International Etf
$7.46
+6.45%
Alger 35 Etf
$7.46
+6.45%
Aadi Bioscience Inc
$7.46
+6.45%
Goldman Sachs Access Inflati
$7.46
+6.45%